Management of Barrett's Esophagus with Proton Pump Inhibitors

Rationale for Long-term PPI Use

Patients with Barrett's esophagus should remain on long-term PPI therapy indefinitely, as PPIs reduce the risk of progression to esophageal adenocarcinoma, according to the American Gastroenterological Association 1, 2
The American Gastroenterological Association explicitly recommends against discontinuing PPIs in patients with Barrett's esophagus 1, 2
Patients with Barrett's esophagus have high levels of nocturnal esophageal acid exposure, which contributes to disease progression 3, 4
PPI therapy is effective for symptom control and healing of esophagitis in Barrett's esophagus patients 4

For patients with Barrett's esophagus who don't respond clinically to once-daily therapy, twice-daily PPI therapy may be recommended 4
Patients with long-segment Barrett's esophagus (>3 cm circumferentially) have particularly high levels of nocturnal acid exposure and may benefit from more aggressive acid suppression 4
There is no definitive evidence that all Barrett's esophagus patients should routinely receive double-dose PPI therapy 4
The goal is to normalize esophageal acid exposure, though clinical studies haven't definitively proven that this reduces cancer risk 4

Anti-reflux surgery (Nissen fundoplication) does not offer advantages over medical treatment with PPIs for preventing progression to dysplasia or cancer in Barrett's esophagus, as stated by the European Society of Gastrointestinal Endoscopy 5, 6
Anti-reflux surgery may be considered as an alternative for patients who are intolerant to PPIs or concerned about long-term PPI medication, according to the American Society for Gastrointestinal Endoscopy 6
NSAIDs/aspirin may decrease esophageal cancer incidence, but the potential benefit may not outweigh medication risks for all patients, as noted by the American Gastroenterological Association 7

Despite PPI therapy, some patients with Barrett's esophagus may still have continued abnormal levels of gastroesophageal reflux even without symptoms 4
Regular endoscopic surveillance remains necessary for Barrett's esophagus patients on PPI therapy to monitor for dysplasia development, as recommended by the American College of Gastroenterology 7
The decision to continue PPI therapy should consider the patient's overall risk profile, including cardiovascular risk factors, as cardiovascular deaths are more common than esophageal adenocarcinoma deaths in Barrett's esophagus patients, according to the American Heart Association 7